<DOC>
	<DOCNO>NCT01175213</DOCNO>
	<brief_summary>The original purpose study ass long-term safety , tolerability , practicability subcutaneous ( SC ) treatment Immune Globulin Subcutaneous Solution ( IGSC ) , 10 % facilitate recombinant human hyaluronidase ( rHuPH20 ) participant Primary Immunodeficiency Diseases ( PID ) complete Baxalta ( formerly Baxter ) Clinical Study Protocol No . 160603 . Following discussion FDA end July 2012 , participant still active study stop treatment rHuPH20 assure safety participant participate study go safety follow-up . During safety follow-up period , participant undergo either SC treatment IGSC , 10 % intravenous ( IV ) treatment Immune Globulin Intravenous ( Human ) ( IGIV ) , 10 % . The IV SC administration route discretion participant investigator .</brief_summary>
	<brief_title>Tolerability Safety Immune Globulin Subcutaneous Solution ( IGSC ) rHuPH20 PID</brief_title>
	<detailed_description>IGSC , 10 % product IGIV , 10 % . IGSC , 10 % generally quote administration subcutaneous ( SC ) IGIV , 10 % generally quote administration intravenous ( IV ) . IGSC , 10 % abbreviated IGI , 10 % ( IMMUNE GLOBULIN INFUSION ( HUMAN ) , 10 % ) In US product license ( trade name GAMMAGARD LIQUID ) IV SC replacement therapy antibody deficiency patient PID . In EU product license ( trade name KIOVIG ) IGSC , 10 % rHuPH20 establish name Immune Globulin Infusion 10 % ( Human ) Recombinant Human Hyaluronidase . US trade name HYQVIA EU trade name HyQvia</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Participant complete complete Baxalta ( formerly Baxter ) Clinical Study Protocol No . 160603 . Participants discontinue rHuPH20 revert intravenous subcutaneous treatment due antirHuPH20 antibody also may enroll longterm safety monitoring . Participant/caretaker review , sign date informed consent Participant willing able comply requirement protocol Participant serious medical condition participant 's safety medical care would impact participation Study 160902 Participant schedule participate another nonBaxalta ( formerly Baxter ) clinical study involve investigational product investigational device course study If female childbearing potential , participant pregnant negative pregnancy test agree employ adequate birth control measure duration study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>